Propanc Biopharma, Inc.: Form 10-Q for the period ended Mar 31, 2015
Filed with the SEC on May 15, 2015 and accepted by EDGAR at May 15, 2015, 15:48 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2015-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2015-01-01 to 2015-03-31 | $9.5k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2014-07-01 to 2015-03-31 | $15.8k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2015-01-01 to 2015-03-31 | −$516.6k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2014-07-01 to 2015-03-31 | −$1.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2015-01-01 to 2015-03-31 | $199.3k | us-gaap:InterestExpense |
| Interest expense | 9 months2014-07-01 to 2015-03-31 | $847.9k | us-gaap:InterestExpense |
| Income tax | 3 months2015-01-01 to 2015-03-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2014-07-01 to 2015-03-31 | −$79.3k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2015-01-01 to 2015-03-31 | −$454.3k | us-gaap:NetIncomeLoss |
| Net income | 9 months2014-07-01 to 2015-03-31 | −$1.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2015-01-01 to 2015-03-31 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2014-07-01 to 2015-03-31 | −$0.01 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months2014-07-01 to 2015-03-31 | −$697.5k | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 9 months2014-07-01 to 2015-03-31 | $918 | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2015-03-31 | $168.3k | us-gaap:Cash |
| Current assets | At period end2015-03-31 | $308.8k | us-gaap:AssetsCurrent |
| Total assets | At period end2015-03-31 | $309.6k | us-gaap:Assets |
| Current liabilities | At period end2015-03-31 | $2.2m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2015-03-31 | −$1.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001144204-15-031499. Last ingested by Listed: Nov 14, 2026, 18:42 ET. Listed shows no prices and gives no investment advice.